Hostname: page-component-77c89778f8-cnmwb Total loading time: 0 Render date: 2024-07-19T20:31:53.830Z Has data issue: false hasContentIssue false
  • English
  • Français

Comparative analysis of plasma metabolomics markers in patients with major depressive disorder and healthy controls

Published online by Cambridge University Press:  01 September 2022

C. Homorogan ,
D. Nitusca ,
V. Enatescu ,
C. Moraru ,
C. Socaciu  and
C. Marian
C. Homorogan*
Affiliation:
Victor Babes University of Medicine and Pharmacy, Biochemistry, Timisoara, Romania
D. Nitusca
Affiliation:
Victor Babes University of Medicine and Pharmacy, Biochemistry, Timisoara, Romania
V. Enatescu
Affiliation:
Victor Babes University of Medicine and Pharmacy Timisoara-Discipline of Psychiatry, Timisoara, Romania and Eduard Pamfil Psychiatry Clinic, Timisoara County Hospital, Psychiatry, Timisoara, Romania
C. Moraru
Affiliation:
RTD Center of Applied Biotechnology BIODIATECH, SC Proplanta, Biotechnology, Cluj-Napoca , Romania
C. Socaciu
Affiliation:
RTD Center of Applied Biotechnology BIODIATECH, SC Proplanta, Biotechnology, Cluj-Napoca , Romania
C. Marian
Affiliation:
Victor Babes University of Medicine and Pharmacy, Biochemistry, Timisoara, Romania
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Mood disorders, including depression, are diseases associated with an increased risk of several metabolic alterations. Metabolomics studies have proved their potential for detecting novel biomarkers of psychiatric diseases.

Objectives

To analyze the plasma metabolite profiling of patients with major depressive disorder (MDD) compared to healthy controls.

Methods

The blood samples were collected from 11 patients diagnosed with MDD and 11 healthy controls, and plasma was separated by centrifugation. The profiles of the metabolites in the plasma samples were determined by Ultra-High Performance Liquid Chromatography-Quadrupole Time of Flight Electrospray Mass Spectrometry (UHPLC-QTOF-MS) in positive mode. The chromatograms were processed by Compass DataAnalysis 4.2 using the Find Molecular Feature (FMF) method and Profile Analysis 2.1 (Bruker, Daltonics) was further used for matrix generation. The MetaboAnalyst online software was used for univariate and multivariate analysis. The mass/charge ratio (m/z values) determined by biostatistics were identified from the Lipidomic Gateway (www.lipidmaps.org) and Human Metabolomic Data Base (www.hmdb.ca).

Results

We found 14 metabolites which could discriminate between cases and controls, having an area under the curve (AUC) in the receiver operating characteristic (ROC) analysis of higher than 0.6. Among these, only two metabolites passed the p<0.05 threshold of statistical significance, one being 2.5 more abundant (p<0.001) in the plasma of MDD patients compared to controls and the other being 1.7 more abundant (p=0.005) in MDD patients compared to controls.

Conclusions

The only metabolite that passed the false discovery rate correction was putatively identified from the metabolomics database as being the phosphatidylcholine PC (16:0/16:0).

Disclosure

No significant relationships.

Keywords

metabolomicsDepression
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S328
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.